DK2294066T3 - Benzoimidazoler som prolylhydroxylaseinhibitorer - Google Patents

Benzoimidazoler som prolylhydroxylaseinhibitorer

Info

Publication number
DK2294066T3
DK2294066T3 DK09739552.9T DK09739552T DK2294066T3 DK 2294066 T3 DK2294066 T3 DK 2294066T3 DK 09739552 T DK09739552 T DK 09739552T DK 2294066 T3 DK2294066 T3 DK 2294066T3
Authority
DK
Denmark
Prior art keywords
benzoimidazoles
prolyl hydroxylase
hydroxylase inhibitors
inhibitors
prolyl
Prior art date
Application number
DK09739552.9T
Other languages
English (en)
Inventor
Frances Meredith Hocutt
Barry Eastman Leonard
Hillary M Peltier
Victor K Phuong
Michael H Rabinowitz
Mark D Rosen
Kyle T Tarantino
Hariharan Venkatesan
Lucy Xiumin Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2294066T3 publication Critical patent/DK2294066T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK09739552.9T 2008-04-28 2009-04-28 Benzoimidazoler som prolylhydroxylaseinhibitorer DK2294066T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4853108P 2008-04-28 2008-04-28
PCT/US2009/041902 WO2009134750A1 (en) 2008-04-28 2009-04-28 Benzoimidazoles as prolyl hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
DK2294066T3 true DK2294066T3 (da) 2014-09-08

Family

ID=40756595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09739552.9T DK2294066T3 (da) 2008-04-28 2009-04-28 Benzoimidazoler som prolylhydroxylaseinhibitorer

Country Status (15)

Country Link
US (8) US8759345B2 (da)
EP (1) EP2294066B9 (da)
JP (5) JP6022769B2 (da)
CN (2) CN105622580B (da)
BR (1) BRPI0911444B8 (da)
CA (1) CA2722772C (da)
CY (1) CY1115621T1 (da)
DK (1) DK2294066T3 (da)
ES (1) ES2523720T3 (da)
HR (1) HRP20141038T2 (da)
PL (1) PL2294066T3 (da)
PT (1) PT2294066E (da)
RU (1) RU2531354C2 (da)
SI (1) SI2294066T1 (da)
WO (2) WO2009134754A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759345B2 (en) * 2008-04-28 2014-06-24 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
ES2360316B1 (es) 2008-12-10 2012-05-08 Antonio Avila Chulia Procedimiento para la encriptación y autentificación de una señal de datos.
WO2010093727A1 (en) 2009-02-10 2010-08-19 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
JP2013500267A (ja) * 2009-07-23 2013-01-07 ヴァンダービルト ユニバーシティー ｍＧＬｕＲ４増強剤としての置換されたベンゾイミダゾールスルホンアミド類および置換されたインドールスルホンアミド類
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
KR20120115252A (ko) * 2009-11-06 2012-10-17 벤더르빌트 유니버시티 Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
CA2811025C (en) 2010-09-10 2018-07-17 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
CN102219745B (zh) * 2011-04-15 2013-10-30 清华大学深圳研究生院 2-芳基取代苯并咪唑类衍生物及其制备方法与应用
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP2758058B1 (en) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013043624A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
ES2818977T3 (es) * 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
US20150239889A1 (en) * 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
KR20190084310A (ko) 2016-11-23 2019-07-16 바이엘 크롭사이언스 악티엔게젤샤프트 살충제로서의 2-[3-(알킬술포닐)-2H-인다졸-2-일]-3H-이미다조[4,5-b]피리딘 유도체 및 유사한 화합물
CN119080881A (zh) 2017-07-07 2024-12-06 伊玛提克斯生物技术有限公司 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
PL3808747T3 (pl) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Związek imidazopirydynonowy
TWI803696B (zh) * 2018-09-14 2023-06-01 日商橘生藥品工業股份有限公司 次黃嘌呤化合物
WO2020072645A1 (en) 2018-10-03 2020-04-09 Akebia Therapeutics, Inc. Benzimidazole derivative for use in the treatment of inflammatory disorders
CN110305072B (zh) * 2019-06-25 2023-09-19 中国药科大学 具有磷酸二酯酶4d和酸性鞘磷脂酶抑制活性的化合物及其应用
US12389911B2 (en) 2019-11-28 2025-08-19 Nihon Nohyaku Co., Ltd. Benzimidazole compound or salt thereof, agricultural and horticultural insecticidal and acaricidal agent containing said compound, and method for using same
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
US20230183241A1 (en) * 2020-03-11 2023-06-15 Kissei Pharmaceutical Co., Ltd. Crystal of a hypoxanthine compound
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
CN112209885A (zh) * 2020-09-07 2021-01-12 宁夏大漠药业有限公司 芬苯达唑生产工艺及生产装置
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
USD1029155S1 (en) 2021-06-25 2024-05-28 Spin Master Ltd. Toy
US11376515B1 (en) * 2021-06-29 2022-07-05 Spin Master Ltd. Transformable toy
WO2023155870A1 (en) * 2022-02-18 2023-08-24 Insilico Medicine Ip Limited Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
US11712636B1 (en) 2022-08-12 2023-08-01 Spin Master Ltd. Transformable toy
US12576341B2 (en) 2022-08-12 2026-03-17 Spin Master Ltd. Transformable toy
WO2025049599A1 (en) 2023-08-29 2025-03-06 President And Fellows Of Harvard College Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60227260A (ja) 1983-11-14 1985-11-12 Toppan Printing Co Ltd セツトアツプ方法
OA08768A (fr) 1986-10-22 1989-03-31 Schering Corp Traitement du virus su SIDA par l'interféron alpha humain recombinant.
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5258362A (en) 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
JP3314938B2 (ja) 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
ZA981936B (en) 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
YU46200A (sh) * 1998-02-27 2003-02-28 Pfizer Products Inc. N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
PT1660491E (pt) 2003-07-28 2008-10-10 Janssen Pharmaceutica Nv Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
US7728025B2 (en) 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
JP2006022769A (ja) * 2004-07-09 2006-01-26 Toyota Motor Corp 内燃機関の排気浄化装置
CN101166745A (zh) * 2005-03-02 2008-04-23 菲布罗根有限公司 噻吩并吡啶化合物和其使用方法
JP2006254624A (ja) * 2005-03-11 2006-09-21 Fuji Electric Holdings Co Ltd 交流交流変換器の制御装置
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US20060276477A1 (en) * 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
WO2008033739A2 (en) 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
CA2672940A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
CA2714111A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo fused pyridones
CA2716798A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
CN101951775A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
JP5557832B2 (ja) 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド
US8759345B2 (en) 2008-04-28 2014-06-24 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
ES2818977T3 (es) * 2011-10-25 2021-04-14 Janssen Pharmaceutica Nv Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico

Also Published As

Publication number Publication date
US8759345B2 (en) 2014-06-24
EP2294066B1 (en) 2014-08-13
US20150284335A1 (en) 2015-10-08
CN105622580A (zh) 2016-06-01
BRPI0911444A2 (pt) 2015-09-29
JP2019167383A (ja) 2019-10-03
CN102076680B (zh) 2016-03-02
RU2010148421A (ru) 2012-06-10
US20140256722A1 (en) 2014-09-11
JP2016147877A (ja) 2016-08-18
JP2021152045A (ja) 2021-09-30
WO2009134750A1 (en) 2009-11-05
US20190367486A1 (en) 2019-12-05
ES2523720T3 (es) 2014-12-01
US20180215732A9 (en) 2018-08-02
EP2294066A1 (en) 2011-03-16
CA2722772A1 (en) 2009-11-05
EP2294066B9 (en) 2015-03-11
JP2011519857A (ja) 2011-07-14
SI2294066T1 (sl) 2014-12-31
US9073923B2 (en) 2015-07-07
US20210078978A1 (en) 2021-03-18
US20140005193A1 (en) 2014-01-02
CN105622580B (zh) 2019-06-21
JP6254624B2 (ja) 2017-12-27
US20180022733A1 (en) 2018-01-25
PL2294066T3 (pl) 2015-02-27
CN102076680A (zh) 2011-05-25
US10851083B2 (en) 2020-12-01
US20110046132A1 (en) 2011-02-24
CY1115621T1 (el) 2017-01-04
HRP20141038T2 (hr) 2015-07-03
JP6022769B2 (ja) 2016-11-09
HK1155447A1 (en) 2012-05-18
US11618744B2 (en) 2023-04-04
PT2294066E (pt) 2014-11-21
CA2722772C (en) 2020-12-22
WO2009134754A1 (en) 2009-11-05
RU2531354C2 (ru) 2014-10-20
BRPI0911444B1 (pt) 2021-03-23
HRP20141038T1 (en) 2014-12-05
JP6900424B2 (ja) 2021-07-07
US20160168127A1 (en) 2016-06-16
JP2018065841A (ja) 2018-04-26
US8865713B2 (en) 2014-10-21
BRPI0911444B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
DK2496236T3 (da) Prolylhydroxylasehæmmere
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2318389T3 (da) Pyridazinderivater som SMO-inhibitorer
ATE546444T1 (de) Amidophenoxyindazole als c-met-hemmer
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
EP2244670A4 (en) INTERSPINED DISTANCE MEMBER
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
EP2326178A4 (en) INHIBITORS OF PROLYL-HYDROXYLASE
ME01858B (me) Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
EP2227770A4 (en) PROLYLHYDROXYLASEINHIBITOREN
DK2349261T3 (da) Pyrazolopyridinderivater som NADPH-oxidaseinhibitorer
EP2273879A4 (en) PROLYLHYDROXYLASEHEMMER
EP2240178A4 (en) PROLYLHYDROXYLASEHEMMER
BRPI0918564A2 (pt) inibidores
EP2224926A4 (en) INHIBITORS OF PROLYL HYDROXYLASES
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
DK2160389T3 (da) Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
DK2160380T3 (da) Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
EP2326179A4 (en) PROLYLHYDROXYLASEHEMMER